Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 10
2004 1
2006 1
2007 5
2008 1
2009 4
2010 11
2011 10
2012 14
2013 12
2014 11
2015 13
2016 16
2017 14
2018 14
2019 17
2020 16
2021 12
2022 10
2023 7
2024 11
2025 17
2026 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

215 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Strosberg J, et al. Among authors: baum rp. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. N Engl J Med. 2017. PMID: 28076709 Free PMC article. Clinical Trial.
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).
Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, Osborne JR, Iravani A, Koo P, Lindenberg L, Baum RP, Bozkurt MF, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen WJG, Rahbar K, Schoder H, Virgolini I, Bodei L, Fanti S, Haberkorn U, Hermann K. Kratochwil C, et al. Among authors: baum rp. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2830-2845. doi: 10.1007/s00259-023-06255-8. Epub 2023 May 29. Eur J Nucl Med Mol Imaging. 2023. PMID: 37246997 Free PMC article.
Recent advances and impending challenges for the radiopharmaceutical sciences in oncology.
Lapi SE, Scott PJH, Scott AM, Windhorst AD, Zeglis BM, Abdel-Wahab M, Baum RP, Buatti JM, Giammarile F, Kiess AP, Jalilian A, Knoll P, Korde A, Kunikowska J, Lee ST, Paez D, Urbain JL, Zhang J, Lewis JS. Lapi SE, et al. Among authors: baum rp. Lancet Oncol. 2024 Jun;25(6):e236-e249. doi: 10.1016/S1470-2045(24)00030-5. Lancet Oncol. 2024. PMID: 38821098 Free PMC article. Review.
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results.
Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, Mueller D, Eismant A, Almaguel F, Zboralski D, Osterkamp F, Hoehne A, Reineke U, Smerling C, Kulkarni HR. Baum RP, et al. J Nucl Med. 2022 Mar;63(3):415-423. doi: 10.2967/jnumed.120.259192. Epub 2021 Jun 24. J Nucl Med. 2022. PMID: 34168013 Free PMC article.
[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.
Walter T, Jann H, Ansquer C, Deshayes E, Garcia-Carbonero R, Teulé A, Baum RP, Verberne HJ, Ćwikła JB, Srirajaskanthan R, de Mestier L, Grana CM, Buck A, Hörsch D, Pavel M, Dierickx LO, Michael M, Strosberg J, Kollár A, Jimenez-Fonseca P, Rinke A, Del Olmo-García M, Flaus A, Hernando J, Kluge A, Breuninger M, Melnyk S, Zhernosekov K, Capdevila J; COMPETE Investigator Team. Walter T, et al. Among authors: baum rp. Lancet. 2026 Jul 18;408(10551):234-247. doi: 10.1016/S0140-6736(26)00604-5. Epub 2026 Jul 2. Lancet. 2026. PMID: 42392118 Clinical Trial.
Editorial: Targeted alpha particle therapy in oncology.
Bruland ØS, Larsen RH, Baum RP, Juzeniene A. Bruland ØS, et al. Front Med (Lausanne). 2023 Mar 7;10:1165747. doi: 10.3389/fmed.2023.1165747. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36960341 Free PMC article. No abstract available.
Current status of FAP therapy in solid tumors.
Siegmund SC, Novruzov E, Mamlins E, Mori Y, Otto S, Canis M, Watabe T, Baum RP, Werner RA, Giesel FL. Siegmund SC, et al. Among authors: baum rp. Semin Nucl Med. 2026 Jan;56(1):40-52. doi: 10.1053/j.semnuclmed.2025.11.022. Epub 2025 Dec 26. Semin Nucl Med. 2026. PMID: 41455672 Free article. Review.
215 results